Outcome measures in pulmonary arterial hypertension associated with systemic sclerosis

Rheumatology

Volumn 47, Issue SUPPL. 5, 2009, Pages

  Kowal Bielecka, O ^a   Delcroix, M ^b   Vonk Noordegraaf, A ^c   Hoeper, M M ^d   Naeije, R ^e,f  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e ERASME HOSPITAL   (Belgium)

^f Department of Pathophysiology ^*  (Belgium)

Author keywords

Exercise capacity; Outcome measure; Pulmonary arterial hypertension; Systemic sclerosis

Indexed keywords

AMBRISENTAN; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SITAXSENTAN; UNIPROST;

AEROBIC EXERCISE; CHRONIC FATIGUE SYNDROME; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFECT; DYSPNEA; HUMAN; LUNG CIRCULATION; LUNG VASCULAR RESISTANCE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SURVIVAL RATE; SURVIVAL TIME; SYMPTOMATOLOGY; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE;

EID: 69949157396     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken308     Document Type: Conference Paper

References (16)

1. Farber HW, Loscalzo. J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-65.
2. Hachulla E, Gressin V, Guillevin L et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. Arthritis Rheum 2005;52:792-800.
3. Naeije R, Huez S. Expert opinion on available options treating pulmonary arterial hypertension. Exp Opin Pharmacother 2007;8:2247-65.
4. McLaughlin V, Presberg KW, Doyle RL et al. Prognosis of pulmonary arterial hypertension" ACCP evidence-based clinical practice guidelines. Chest 2004;126:78S-92S.
5. Fleg JL, Pina IL, Balady GJ. Assessment of functional capacity in clinical and research applications: An advisory from the committee on exercise, rehabilitation, and prevention, council on clinical cardiology, American Heart Association. Circulation 2000;102:1591-7.
6. Naeije R, Huez S. Right ventricular function in pulmonary hypertension: physiological concepts. Eur Heart J 2007;9H:17S-21S.
7. Miyamoto S, Nagaya N, Satoh T et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-92.
8. Galiè N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:81S-8S.
9. Avouac J, Wipff J, Kahan A, Allanore Y. Effects of oral treatments on exercise capacity in systemic sclerosis-related pulmonary arterial hypertension: A meta-analysis of randomised controlled trials. Ann Rheum Dis 2008;67:808-14.
10. Peacock AJ, Naeije R, Galie N, Reeves JT. End points in pulmonary arterial hypertension: The way forward. Eur Respir J 2004;23:947-53.
11. Distler O, Behrens F, Huscher D et al. Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis. Rheumatology 2006;45:1455-7.
12. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of diseases. Ann Intern Med 2000;132:425-34.
13. Lagakos SW. The challenge of subgroup analyses - reporting without distorting. N Engl J Med 2006;355:1667-9.
14. Williams MH, Das C, Handler CE et al. Systemic sclerosis associated pulmonary hypertension: Improved survival in the current era. Heart 2006;92:926-32.
15. Redelmeyer DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small differences in functional status: The six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997;155:1278-82.
16. Simonneau G, Barst RJ, Galie N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;162:800-4.